Literature DB >> 10981108

Current studies in pharmacoeconomics.

J J Caro1.   

Abstract

Mesh:

Substances:

Year:  1999        PMID: 10981108     DOI: 10.1007/s11906-996-0018-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  8 in total

1.  Public-health rounds at the Harvard School of Public Health. Allocation of resources to manage hypertension.

Authors:  W B Stason; M C Weinstein
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

2.  The cost-effectiveness of hypertension treatment in Sweden: an analysis of the criteria for intervention and the choice of drug treatment.

Authors:  M Johannesson
Journal:  J Hum Hypertens       Date:  1996-02       Impact factor: 3.012

3.  A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.

Authors:  R J Milne; S Vander Hoorn; R T Jackson
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

4.  Implementation of local guidelines for cost-effective management of hypertension. A trial of the firm system.

Authors:  J N Aucott; E Pelecanos; R Dombrowski; S M Fuehrer; J Laich; D C Aron
Journal:  J Gen Intern Med       Date:  1996-03       Impact factor: 5.128

5.  Cost-effectiveness of felodipine-metoprolol (Logimax) and enalapril in the treatment of hypertension.

Authors:  F Andersson; B Kartman; O K Andersson
Journal:  Clin Exp Hypertens       Date:  1998-11       Impact factor: 1.749

6.  Improving cost-effectiveness of hypertension management at a community health centre.

Authors:  P R Edwards; D W Lunt; G S Fehrsen; C J Lombard; K Steyn
Journal:  S Afr Med J       Date:  1998-05

7.  Cost-minimization and the number needed to treat in uncomplicated hypertension.

Authors:  K A Pearce; C D Furberg; B M Psaty; J Kirk
Journal:  Am J Hypertens       Date:  1998-05       Impact factor: 2.689

8.  The direct costs to the NHS of discontinuing and switching prescriptions for hypertension.

Authors:  D Hughes; A McGuire
Journal:  J Hum Hypertens       Date:  1998-08       Impact factor: 3.012

  8 in total
  2 in total

1.  Comparative cost-effectiveness analysis of oral triptan therapy for migraine in four European countries.

Authors:  Manuel Hens; Ana Villaverde-Hueso; Veronica Alonso; Ignacio Abaitua; Manuel Posada de la Paz
Journal:  Eur J Health Econ       Date:  2013-07-10

Review 2.  The economic impact of hypertension.

Authors:  William J Elliott
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 May-Jun       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.